Company intelligence / Profile preview
argenx
Amsterdam, Netherlandsargenx.com ↗
- Ownership
- Public · ARGX
- Employees
- ~800
- Development stage
- Commercial
01
Overview
argenx has successfully commercialized VYVGART/efgartigimod as the first-and-only approved FcRn blocker for generalized myasthenia gravis in adults across the US, EU, Japan and other regions. The company continues to expand efgartigimod into additional indications such as CIDP and has a robust pipeline of antibody-based therapies targeting severe autoimmune diseases. Clinical results have demonstrated efficacy leading to regulatory approvals for multiple indications.[2][3]
- Therapeutic areas
- ImmunologyNeurology
- Modalities
- Monoclonal antibodies (mAbs)Antibody fragments
- Industry
- Biotech
02
Drug pipeline
19 assets18 more assets in the full pipeline.
03
Partnerships
Zai Lab (China commercialization)FUJIFILM Diosynth Biotechnologies (manufacturing services)Broteio Pharma B.V.Leiden University Medical Centervarious academic collaborations via IIP program[1][3]
04
Financials
- Market cap
- $53.3B
- Total revenue
- $4.2B
- Enterprise value
- $48.2B
Beyond the preview
Go deeper on argenx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on argenx.